📣 In June 2021, Novartis International AG announced receiving approval from the US Food & Drug Administration (FDA) for the Breakthrough Therapy Designation (BTD) to 177Lu-PSMA-617 in patients with conditions of metastatic castration-resistant prostate cancer (mCRPC).
▶️ 𝐕𝐢𝐞𝐰 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:- https://www.marknteladvisors.c....om/research-library/
#prostate_cancer_market #prostatecancer #cancer #biopharma #ultrasound #tumor #healthcare #marknteladvisors #marketresearch
Like
Comment
Share
1 (877) 773-1002